{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:00:44Z","timestamp":1794254444471,"version":"4.9.0"},"reference-count":83,"publisher":"Elsevier","isbn-type":[{"value":"9780128241431","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.pmbts.2020.10.002","type":"book-chapter","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:29:11Z","timestamp":1606994951000},"page":"157-173","source":"Crossref","is-referenced-by-count":21,"title":["Early detection and personalized medicine: Future strategies against Alzheimer's disease"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pmbts.2020.10.002_bb0010","volume":"16","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0015","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.14283\/jpad.2019.23","article-title":"Editorial: failure after failure. what next in AD drug development?","volume":"6","author":"Aisen","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"9","key":"10.1016\/bs.pmbts.2020.10.002_bb0025","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0030","first-page":"1687","article-title":"The use of statins in patients with heart failure: more questions than answers","volume":"7","author":"Westman","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fmed.2018.00108","article-title":"The role of genetics in advancing precision medicine for Alzheimer's disease-a narrative review","volume":"5","author":"Freudenberg-Hua","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0040","article-title":"Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies","author":"Zetterberg","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","article-title":"Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective","volume":"120","author":"Tanzi","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-017-0169-9","article-title":"Soluble oligomeric amyloid-\u03b2 induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain","volume":"12","author":"Arbel-Ornath","year":"2017","journal-title":"Mol Neurodegener"},{"issue":"28","key":"10.1016\/bs.pmbts.2020.10.002_bb0080","doi-asserted-by":"crossref","first-page":"E3699","DOI":"10.1073\/pnas.1510329112","article-title":"Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques","volume":"112","author":"Gowrishankar","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","article-title":"Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A\u03b2 generation in Alzheimer's disease","volume":"132","author":"Sadleir","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nm.4443","article-title":"Amyloid-\u03b2 plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation","volume":"24","author":"He","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer's disease","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.arr.2012.06.008","article-title":"Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res Rev"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","article-title":"Inflammation in neurodegenerative disease\u2014a double-edged sword","volume":"35","author":"Wyss-Coray","year":"2002","journal-title":"Neuron"},{"issue":"5440","key":"10.1016\/bs.pmbts.2020.10.002_bb0110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.pmbts.2020.10.002_bb0115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0892-345","article-title":"A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid","volume":"1","author":"Mullan","year":"1992","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0120","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/emboj.2012.79","article-title":"The mechanism of \u03b3-secretase dysfunction in familial Alzheimer disease","volume":"31","author":"Ch\u00e1vez-Guti\u00e9rrez","year":"2012","journal-title":"Embo J"},{"issue":"7","key":"10.1016\/bs.pmbts.2020.10.002_bb0125","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/febs.14004","article-title":"The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the \"amyloid cascade hypothesis\"","volume":"284","author":"Hardy","year":"2017","journal-title":"Febs J"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0130","doi-asserted-by":"crossref","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","article-title":"The genetics of Alzheimer disease","volume":"2","author":"Tanzi","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2020.10.002_bb0135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"5123","key":"10.1016\/bs.pmbts.2020.10.002_bb0140","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1326-1-15","article-title":"The generation and function of soluble apoE receptors in the CNS","volume":"1","author":"Rebeck","year":"2006","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","article-title":"Apolipoprotein E, receptors, and modulation of Alzheimer's disease","volume":"83","author":"Zhao","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/bs.pmbts.2020.10.002_bb0160","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1172\/JCI36663","article-title":"apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain","volume":"118","author":"Deane","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer's disease: mechanisms, genetics, and lessons from other pathologies","volume":"13","author":"Foster","year":"2019","journal-title":"Front Neurosci"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0170","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/bs.pmbts.2020.10.002_bb0175","doi-asserted-by":"crossref","first-page":"e1745","DOI":"10.1212\/WNL.0000000000007231","article-title":"Relative risk for Alzheimer disease based on complete family history","volume":"92","author":"Cannon-Albright","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer's disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"38","key":"10.1016\/bs.pmbts.2020.10.002_bb0185","doi-asserted-by":"crossref","first-page":"13461","DOI":"10.1073\/pnas.0503689102","article-title":"Neuronal sorting protein-related receptor sorLA\/LR11 regulates processing of the amyloid precursor protein","volume":"102","author":"Andersen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058618","article-title":"SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians","volume":"8","author":"Miyashita","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.pmbts.2020.10.002_bb0195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2013.1","article-title":"Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology","volume":"18","author":"Chapuis","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"28","key":"10.1016\/bs.pmbts.2020.10.002_bb0200","doi-asserted-by":"crossref","first-page":"10886","DOI":"10.1074\/jbc.RA118.005385","article-title":"CD2-associated protein (CD2AP) overexpression accelerates amyloid precursor protein (APP) transfer from early endosomes to the lysosomal degradation pathway","volume":"294","author":"Furusawa","year":"2019","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/bs.pmbts.2020.10.002_bb0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb0210","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuron.2013.04.014","article-title":"Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta","volume":"78","author":"Griciuc","year":"2013","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0215","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/mp.2011.24","article-title":"Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b\/C4b binding sites","volume":"17","author":"Brouwers","year":"2012","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0220","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","article-title":"TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-Beta by microglia","volume":"91","author":"Yeh","year":"2016","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.conb.2019.11.024","article-title":"Genetics of Alzheimer's disease: where we are, and where we are going","volume":"61","author":"Bellenguez","year":"2020","journal-title":"Curr Opin Neurobiol"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11910-017-0787-1","article-title":"Genetics of Alzheimer's disease: the importance of polygenic and epistatic components","volume":"17","author":"Raghavan","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.24999","article-title":"Polygenic risk score analysis of pathologically confirmed Alzheimer disease","volume":"82","author":"Escott-Price","year":"2017","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/bs.pmbts.2020.10.002_bb0245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.0000000000002922","article-title":"Polygenic risk of Alzheimer disease is associated with early- and late-life processes","volume":"87","author":"Mormino","year":"2016","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/bs.pmbts.2020.10.002_bb0250","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.1212\/WNL.0000000000005415","article-title":"Dissociable influences of APOE \u025b4 and polygenic risk of AD dementia on amyloid and cognition","volume":"90","author":"Ge","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.pmbts.2020.10.002_bb0255","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ana.25029","article-title":"Polygenic hazard scores in preclinical Alzheimer disease","volume":"82","author":"Tan","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0260","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2015.12.023","article-title":"The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume","volume":"40","author":"Lupton","year":"2016","journal-title":"Neurobiol Aging"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb0265","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3233\/JAD-160707","article-title":"Genetic risk as a marker of amyloid-\u03b2 and tau burden in cerebrospinal fluid","volume":"55","author":"Voyle","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0270","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2147\/NDT.S62323","article-title":"Disease progression model for clinical dementia rating-sum of boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's disease neuroimaging initiative","volume":"10","author":"Samtani","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0275","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog): modifications and responsiveness in pre-dementia populations. A narrative review","volume":"63","author":"Kueper","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0280","article-title":"Composite cognitive and functional measures for early stage Alzheimer's disease trials","volume":"12","author":"Schneider","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mcn.2018.12.004","article-title":"Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease","volume":"97","author":"Cohen","year":"2019","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0290","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer's disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0295","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer's disease","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"17","key":"10.1016\/bs.pmbts.2020.10.002_bb0300","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.pmbts.2020.10.002_bb421","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00401-017-1740-8","article-title":"[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging","volume":"13","author":"Marqui\u00e9","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb418","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies","volume":"81","author":"Marqui\u00e9","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0315","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary tau PET radioligand","volume":"60","author":"Betthauser","year":"2019","journal-title":"J Nucl Med"},{"issue":"Pt. 9","key":"10.1016\/bs.pmbts.2020.10.002_bb0320","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/brain\/awv181","article-title":"Cerebrospinal fluid tau and amyloid-\u03b21-42 in patients with dementia","volume":"138","author":"Skillb\u00e4ck","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0325","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ana.1054","article-title":"Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease","volume":"50","author":"Itoh","year":"2001","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/bs.pmbts.2020.10.002_bb0330","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/bs.pmbts.2020.10.002_bb0335","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/bs.pmbts.2020.10.002_bb0340","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2020.10.002_bb0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","article-title":"The clinical use of structural MRI in Alzheimer disease","volume":"6","author":"Frisoni","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.1016\/bs.pmbts.2020.10.002_bb0350","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/bs.pmbts.2020.10.002_bb0355","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"issue":"Suppl. 1","key":"10.1016\/bs.pmbts.2020.10.002_bb0360","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.neurobiolaging.2011.09.007","article-title":"Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments","volume":"32","author":"Reiman","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0365","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0370","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","article-title":"Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease","volume":"11","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/bs.pmbts.2020.10.002_bb419","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/brain\/awx120","article-title":"Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease","volume":"140","author":"Parbo","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.2011.147","article-title":"An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28","volume":"32","author":"Owen","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"10.1016\/bs.pmbts.2020.10.002_bb0380","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-Calvet","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0385","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/bs.pmbts.2020.10.002_bb0390","first-page":"965","article-title":"Promising results in 18-month analysis of Alzheimer drug candidate","volume":"320","author":"Abbasi","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0395","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/bs.pmbts.2020.10.002_bb0400","first-page":"272","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/bs.pmbts.2020.10.002_bb0405","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI96429","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","volume":"128","author":"Liao","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/bs.pmbts.2020.10.002_bb0410","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41467-019-09118-9","article-title":"Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model","volume":"10","author":"Zhong","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/bs.pmbts.2020.10.002_bb0415","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1084\/jem.20182386","article-title":"Sex-specific effects of microbiome perturbations on cerebral A\u03b2 amyloidosis and microglia phenotypes","volume":"216","author":"Dodiya","year":"2019","journal-title":"J Exp Med"}],"container-title":["Progress in Molecular Biology and Translational Science","Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117320301691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117320301691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T04:02:57Z","timestamp":1761796977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117320301691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128241431"],"references-count":83,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2020.10.002","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}